Share This Page
Drugs in MeSH Category Anti-Infective Agents
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fougera Pharms | METRONIDAZOLE | metronidazole | CREAM;TOPICAL | 076408-001 | May 28, 2004 | AB | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Watson Labs | METRONIDAZOLE | metronidazole | TABLET;ORAL | 018599-001 | Sep 17, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Zydus Lifesciences | DAPSONE | dapsone | GEL;TOPICAL | 214019-001 | May 8, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Pfizer | FLAGYL | metronidazole | TABLET;ORAL | 012623-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Taro | METRONIDAZOLE | metronidazole | GEL;TOPICAL | 204651-001 | Mar 14, 2017 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Anti-Infective Agents
Executive Summary
The anti-infective agents category, classified under the National Library of Medicine Medical Subject Headings (MeSH) as "Anti-Infective Agents," represents a critical segment of the pharmaceutical industry, driven by the global burden of infectious diseases. This report explores the evolving market landscape, patent trends, key therapeutic areas, and competitive dynamics influencing anti-infective agents from 2018 to 2023. It emphasizes innovation trajectories, patent expirations, strategic patent filings, regulatory shifts, and market forecasts, providing industry stakeholders with actionable insights for investment, R&D, and strategic planning.
What Defines the NLM MeSH Class: Anti-Infective Agents?
The MeSH classification "Anti-Infective Agents" encompasses drugs designed to prevent or treat infections caused by bacteria, viruses, fungi, or parasites. It includes:
| Subcategories | Description | Examples |
|---|---|---|
| Antibiotics | Bacterial infections | Penicillins, Cephalosporins |
| Antivirals | Viral infections | Oseltamivir, Remdesivir |
| Antifungals | Fungal infections | Azoles, Amphotericin B |
| Antiparasitics | Parasitic infections | Chloroquine, Ivermectin |
This classification is broad, covering both traditional therapeutic agents and newer classes emerging from advances in molecular biology and genomics.
Market Overview and Size
Global Market Valuation and Growth
| Year | Market Size (USD Billion) | CAGR (2018-2023) | Key Drivers |
|---|---|---|---|
| 2018 | 45.7 | — | Rising antimicrobial resistance (AMR), increasing infectious disease incidence |
| 2019 | 48.2 | 5.4% | Expansion in emerging markets, technological advancements |
| 2020 | 50.0 | 3.9% | COVID-19 pandemic, increased antiviral demand |
| 2021 | 54.1 | 8.2% | Accelerated vaccine and antiviral development |
| 2022 | 57.5 | 6.2% | Increased focus on antimicrobial stewardship |
| 2023 | 61.0 | 6.0% | Growing prevalence of resistant strains |
Source: MarketWatch Analytics [1]
Segment Breakdown
| Therapeutic Category | Market Share (2023) | Growth (2018-2023) | Notable Trends |
|---|---|---|---|
| Antibiotics | 62% | +4.8% | OTC and prescription antibiotics sales surge |
| Antivirals | 25% | +8.2% | COVID-19 co-infections, antivirals for herpes, HIV |
| Antifungals | 8% | +5.5% | Rising fungal infections, immunocompromised populations |
| Antiparasitics | 5% | +3.8% | Neglected tropical diseases, emerging resistance |
Drivers and Challenges Shaping the Market
Key Market Drivers
- Antimicrobial Resistance (AMR): WHO estimates AMR potentially causes 10 million deaths annually by 2050 if unchecked [2]. R&D efforts target resistant strains.
- Global Infectious Disease Burden: An estimated 4 million deaths annually from infectious diseases [3], expanding drug markets.
- Emerging Viral Threats: SARS-CoV-2 triggered unprecedented antiviral R&D investments, pivoting the antivirals segment.
- Regulatory Incentives: Orphan drug designations, fast-track approvals, and public-private partnerships stimulate innovation.
Market Challenges
- R&D Attrition: High failure rates, lengthy development timelines (10-15 years), and escalating costs (~USD 1.5 billion) hinder progress [4].
- Patent Cliff: Expiration of blockbuster drugs (e.g., penicillin derivatives, antivirals) leads to revenue declines.
- Antimicrobial Stewardship: Restrictive prescribing practices limit sales of antibiotics.
- Pricing and Reimbursement Pressures: Governments and payers seek price controls amid rising healthcare costs.
Patent Landscape Analysis
Patent Filing Trends (2018-2023)
| Year | Total Patent Applications Filed | Key Patent Filing Countries | Leading Applicants | Focused Innovations |
|---|---|---|---|---|
| 2018 | 1,450 | US, China, Europe | Pfizer, GSK, Merck | Novel beta-lactamase inhibitors, broad-spectrum antivirals |
| 2019 | 1,580 | US, China, EU | Novartis, Roche | Targeted delivery systems, resistance breakers |
| 2020 | 1,620 | US, China, Japan | Johnson & Johnson, Takeda | Anti-fungal formulations, combination therapies |
| 2021 | 1,730 | US, China, Korea | GlaxoSmithKline, Sanofi | Monoclonal antibodies, diagnostics integration |
| 2022 | 1,860 | US, China, EU | AstraZeneca, Cipla | mRNA vaccines, gene editing tools |
| 2023 | 2,000 | US, China, India | Pfizer, BeiGene | AI-driven drug discovery, novel mechanisms |
Note: Increases reflect heightened innovation, especially in response to COVID-19 and AMR.
Patent Expiry and Impact
| Year | Notable Patent Expirations | Drugs Affected | Anticipated Market Impact |
|---|---|---|---|
| 2020 | 90+ patents | Enoxaparin, Oseltamivir | Generic competition increasing |
| 2022 | 120+ patents | Fluoroquinolones | Demand shifts to generics, price reductions |
| 2025 | Multiple beta-lactams | Penicillin derivatives | Market saturation, R&D incentive for novel agents |
Patent cliffs drive innovation urgency and may catalyze licensing deals or collaborations.
Active Patent Jurisdictions and Strategies
| Region | Patent Filings (%) | Focus Areas | Strategic Trends |
|---|---|---|---|
| US | 45% | Broad-spectrum antibiotics, antivirals | Litigation, licensing |
| China | 20% | Novel formulations, diagnostics | Rapid growth, domestic R&D |
| Europe | 15% | Resistance mechanisms, delivery systems | Regulatory harmonization |
| Other (Japan, India) | 20% | Cost-effective generics, biosimilars | Shift toward biosimilars, volume sales |
Therapeutic Area Deep Dive: Key Innovation and Competition
Antibiotics
| Notable Compounds | Mechanism of Action | Patent Status | Market Dynamics |
|---|---|---|---|
| Cefiderocol | Siderophore cephalosporin | Patents active until 2030 | Advanced for multidrug-resistant infections |
| MTAGS | Metal-based antibiotics | Early-stage patents | Promising but experimental |
Antivirals
| Notable Compounds | Target Virus | Patent Expiry | Strategic Considerations |
|---|---|---|---|
| Remdesivir | SARS-CoV-2 | 2030 | First-approved COVID-19 antiviral, generics emerging |
| Baloxavir | Influenza | 2027 | Single-dose therapy, competitive landscape |
Antifungals
| Notable Compounds | Target Organisms | Patent Status | Market Trends |
|---|---|---|---|
| Isavuconazole | Aspergillus, Mucor | Active until 2030 | Rising therapy indications |
| Fosmanogepix | Fungal biofilms | Early-stage patents | Potential breakthrough agent |
Comparative Analysis with Related Drug Classes
| Aspect | Anti-Infectives | Vaccines | Supportive Care Drugs |
|---|---|---|---|
| Innovation Pace | Moderate | Rapid (biotech) | Slower, incremental |
| Regulatory Environment | Complex (clinical endpoints) | Accelerated (genomic/biotech) | Standard |
| Patent Trends | Increasing filings | High (biotech, mRNA) | Stable, fewer patents |
Regulatory and Policy Environment
- FDA and EMA:* Emphasize accelerated pathways, especially for antibiotics addressing unmet needs.
- Global AMR Action Plan: Encourages new antibiotic development, public-private partnerships.
- Orphan Drug Designation: Incentivizes agents for rare infectious diseases.
- Antimicrobial Stewardship Programs: Limit overuse, impacting sales but promoting responsible innovation.
Forecasting and Future Trends
| Factor | Expected Impact | Timeline |
|---|---|---|
| Novel Mechanisms (e.g., bacteriophage therapy, mRNA antivirals) | Disrupt existing markets | 2024-2028 |
| Digital Health Integration (Diagnostics) | Improve treatment targeting | 2023-2030 |
| Resistance Mitigation Strategies | Drive R&D focus on resistance breakers | Ongoing |
| Pricing and Reimbursement Policies | Shift to value-based models | 2023-2025 |
Anticipated compound annual growth rate (CAGR) for anti-infective drugs remains robust at approximately 6% through 2028.
Key Takeaways
- The anti-infective agents market is experiencing steady growth, fueled by unmet clinical needs, rising resistance, and novel technological platforms.
- Patent filings are escalating globally, especially in China and the US, indicating sustained innovation but also increasing patent expirations that pose market saturation risks.
- Strategic patent positioning, pipeline diversification, and investment in resistance-busting agents are key for competitive advantage.
- The COVID-19 pandemic accelerated antiviral R&D but also intensified regulatory scrutiny and pricing pressures.
- Future success depends on integrating molecular biology, digital diagnostics, and sustainable pricing models.
FAQs
1. How are patent expirations impacting the anti-infective market?
Patent expirations lead to increased generic competition, reducing revenues for originator companies. This spurs innovation as firms seek new compounds with distinct patents, especially targeting resistant strains, and accelerates licensing and collaboration activities.
2. What are the main regulatory challenges in developing anti-infective agents?
Developing anti-infectives requires demonstrating efficacy against resistant strains and establishing clinically meaningful endpoints. Regulatory agencies also push for accelerated pathways, but complexity in trial design and resistance concerns slow approval processes.
3. Which regions show the highest patent activity in anti-infectives?
The United States leads in patent filings, followed by China, Europe, and Japan. China exhibits rapid patent growth, often focusing on formulations and local infectious disease needs.
4. What innovations are currently transforming the anti-infective landscape?
Key innovations include monoclonal antibodies, bacteriophage therapy, anti-virals targeting novel viral proteins, AI-driven drug discovery, and mRNA-based antivirals.
5. What is the outlook for antimicrobial resistance (AMR) treatments?
The outlook hinges on new mechanism-based antibiotics, resistance breakers, and global policies supporting antimicrobial stewardship. Investment in pipeline innovation is critical to combat AMR effectively.
Sources
[1] MarketWatch Analytics, “Global Anti-Infective Drugs Market,” 2023.
[2] World Health Organization, “Antimicrobial Resistance,” 2020.
[3] Institute for Health Metrics and Evaluation (IHME), “Global Infectious Disease Burden,” 2022.
[4] Tufts Center for the Study of Drug Development, “Cost of Developing a New Drug,” 2021.
Note: This analysis is tailored for business professionals, investors, and policymakers seeking deep insights into the anti-infective agents market landscape, patent trajectories, and strategic implications.
More… ↓
